Boston, MA - An immunosuppressive agent recently in the news for its role in drug-eluting stents has proved significantly more effective than azathioprine in reducing the severity and incidence of ...

Aug. 27, 2003 -- Everolimus is more efficacious than azathioprine in reducing severity and incidence of cardiac-allograft vasculopathy, according to the results of a randomized trial published in the ...

Cardiac allograft vasculopathy (CAV), the major limitation to long term survival after heart transplantation, occurs when blood vessels in a transplanted heart progressively narrow and lead to ...

Background Coronary allograft vasculopathy is a severe complication of heart transplantation. We used virtual histology intravascular ultrasound to characterize plaque burden and tissue composition ...

LOS ANGELES, CA—Within 5 years of heart transplant, patients with Medicaid insurance are more likely to suffer from cardiac allograft vasculopathy (CAV)—a leading cause of mortality in these ...

The trial did not meet its primary end point for reducing plaque progression. The National Institutes of Health–funded CAVIAR—Cardiac Allograft Vasculopathy Inhibition with AliRocumab—trial included ...

We thank Dr Labarrere and colleagues for their discussion of the pivotal findings described in our paper on the assessment of coronary allograft vasculopathy by virtual histology-intravascular ...

A new study led by UCLA Health highlights the link between socioeconomic disadvantage, Medicaid insurance, and poorer survival rates after heart transplantation. Researchers found that ...

Cardiac allograft vasculopathy (CAV), the major limitation to long term survival after heart transplantation, can lead to dysfunction of the heart muscle or sudden death. Appropriate treatment for ...

New York, New York, June 25, 2010 – Cardiac allograft vasculopathy (CAV), the major limitation to long term survival after heart transplantation, occurs when blood vessels in a transplanted heart ...